Skip to main content

3 Result(s)

within J-S Frenel Remove this filter Biomedicine Remove this filter

and

  1. No Access

    Article

    Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer

    Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody–drug conjugates (ADCs): Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd), ...

    F. Poumeaud, M. Morisseau, L. Cabel, A. Gonçalves, C. Rivier… in British Journal of Cancer (2024)

  2. No Access

    Article

    Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation

    Efficacy of endocrine therapy in HR+/HER2− metastatic breast cancer could differ depending on the presence of BRCA1/2 germline mutation.

    J.-S. Frenel, A. Lusque, S. Delaloge, J.-M. Ferrero… in British Journal of Cancer (2023)

  3. Article

    Open Access

    Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas

    Carcinoma cells lack syndecan-1 expression when they are transiting from an epithelial to a less-differentiated mesenchymal phenotype (epithelial–mesenchymal transition, EMT). Furthermore, a shift of syndecan-...

    D Loussouarn, L Campion, C Sagan, J-S Frenel, F Dravet… in British Journal of Cancer (2008)

    Download PDF (1209 KB) View Article